pramlintide Articles
Amylin and Takeda drop combo obesity drug development
8 August 2011
Amylin narrows 1st-qtr loss 34% to $47M
20 April 2009
Amylin's loss deeper on Byetta worries
9 February 2009
Amylin hits 6-year low on Byetta LAR concerns
3 November 2008
Amylin's 2nd-qtr 2008 loss widens to $64.8M
4 August 2008
Amylin's loss for 4th-qtr 2007 worsens 32%
4 February 2008
Amylin's 3rd-qtr net loss narrows to $39.8M
29 October 2007
Stock Commentary - New York week to Oct 8, 2007
15 October 2007
Stock Commentary - New York week to July 30, 2007
6 August 2007
Stock Commentary - New York week to July 9, 2007
16 July 2007
Amylin's 1st-qtr 2007 net loss narrows 27.2%
23 April 2007
Amylin's loss narrows 13.1% in 4th-qtr
12 February 2007
Amylin's losses down 37% in 3rd-qtr
30 October 2006
Amylin's 2nd-qtr loss deepens to $46.4M
31 July 2006
Stock Commentary - New York week to Mar 20, 2006
27 March 2006
Amylin's pramlintide performs well in Ph II
20 February 2006
Amylin's 2nd-qtr loss narrows 32% to $26.6M
15 August 2005
Amylin EPS loss inches up 7.5% to $0.43
16 May 2005
Stock Commentary - New York week to Oct 4
11 October 2004
Stock Commentary - New York
16 February 2004
Amylin withdraws Swiss filing for Symlin
19 January 2004
Amylin faces SEC inquiry
5 January 2004
Stock Commentary - New York
5 January 2004
Amylin's Symlin US approval on hold
22 December 2003
Amylin joins Russell 1000 Index
21 July 2003
Amlyin prices $150M private placement
30 June 2003
Losses grow at Amylin on costly Phase III trials
19 May 2003
Amylin files New Symlin data in Switzerland
7 April 2003
Stock Commentary - week to Jan 20 - New York
27 January 2003
Amylin to take Symlin back to clinic
7 January 2002
Amylin to take Symlin back to clinic
28 December 2001
Stock Commentary - New York
18 October 2001
Amylin must conduct more Symlin studies
15 October 2001
Stock Commentary - New York
30 August 2001
Amylin diabetes drug shown to abate nausea
13 August 2001
Stock Commentary - New York
2 August 2001
Stock Commentary - New York
1 August 2001
Stock Commentary - New York
21 June 2001
Stock Commentary - New York
7 June 2001
Amylin submits EU application for Symlin
5 June 2001
Amylin placement raises $35 million
1 June 2001
Genomics may increase costs of NCE development, says Lehman Bros
22 February 2001
Amylin files Symlin NDA in USA
7 December 2000
Stock Commentary - New York
7 December 2000
Amylin to start Ph III diabetes trial in 2001
6 November 2000
Amylin first-quarter net loss deepens
18 May 2000
Amylin's exendin-4 shows promise in Ph II
11 January 2000
Stock Commentary New York
18 November 1999
Stock Commentary New York
11 November 1999
Amylin to file for Symlin OK in mid-2000
10 November 1999
Stock Commentary New York
14 October 1999
Stock Commentary New York
23 September 1999
Stock Commentary New York
16 September 1999
Stock Commentary New York
9 September 1999
Showing 1-62 of 62 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
